Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Block Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Block Inc trades at $81.75 (market cap $47.61B). The key difference: Block Inc is far larger — about 5.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Block Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | XYZ | |
|---|---|---|
Market Cap | $8.04B | $47.61B |
Sector | Health | Technology |
52-Week High | $339.75 | $81.11 |
52-Week Low | $241.71 | $49.04 |
Enterprise Value | $7.85B | $42.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Block (XYZ) trades at $78.72, up 1.84% today, with a bullish technical outlook and strong analyst support (26 buy ratings). Recent earnings beat expectations in Q1 2026, though net income margin narrowed to 3.3% in 2025. The company faces a $45 million settlement over Cash App fraud allegations but continues to invest in AI and Square growth.
The stock offers upside to the $88.53 consensus target, driven by earnings momentum and AI initiatives, but risks include regulatory scrutiny, rising credit losses, and volatile cash flow. Investors should weigh solid long-term growth prospects against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
